Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Yothers

Showing results (31-40 of 115) with videos related to

Pageof 12
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 30, 2024
Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04John Devin Peipert, Jessica Roydhouse, Mourad Tighiouart, et al.
Cancer|September 14, 2007
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysisJ Philip Kuebler, Linda Colangelo, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2021
Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35N Lynn Henry, Sungjin Kim, Ron D Hays, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28Eleftherios P Mamounas, John Bryant, Barry Lembersky, et al.
Forum of Clinical Oncology|March 19, 2016
Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting analysis dates for the IDEA collaborationLindsay A Renfro, Axel M Grothey, James Paul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01Hiroko Kunitake, Ping Zheng, Greg Yothers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trialsFrank A Sinicrope, Nathan R Foster, Harry H Yoon, et al.
Future Oncology (London, England)|June 25, 2026
EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual diseaseAnwaar Saeed, Greg Yothers, Shannon L Puhalla, et al.
Journal of the National Cancer Institute|June 6, 2002
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experienceSoonmyung Paik, John Bryant, Elizabeth Tan-Chiu, et al.
Journal of the National Cancer Institute|February 25, 2020
Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity IndexGillian Gresham, Márcio A Diniz, Zahra S Razaee, et al.
Pageof 12

Showing results (31-40 of 115) with videos related to

Sort By:
Pageof 12
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 30, 2024
Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04John Devin Peipert, Jessica Roydhouse, Mourad Tighiouart, et al.
Cancer|September 14, 2007
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysisJ Philip Kuebler, Linda Colangelo, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2021
Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35N Lynn Henry, Sungjin Kim, Ron D Hays, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28Eleftherios P Mamounas, John Bryant, Barry Lembersky, et al.
Forum of Clinical Oncology|March 19, 2016
Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting analysis dates for the IDEA collaborationLindsay A Renfro, Axel M Grothey, James Paul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01Hiroko Kunitake, Ping Zheng, Greg Yothers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trialsFrank A Sinicrope, Nathan R Foster, Harry H Yoon, et al.
Future Oncology (London, England)|June 25, 2026
EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual diseaseAnwaar Saeed, Greg Yothers, Shannon L Puhalla, et al.
Journal of the National Cancer Institute|June 6, 2002
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experienceSoonmyung Paik, John Bryant, Elizabeth Tan-Chiu, et al.
Journal of the National Cancer Institute|February 25, 2020
Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity IndexGillian Gresham, Márcio A Diniz, Zahra S Razaee, et al.
Pageof 12